WO1995011673A1 - Composes et procedes de traitement de la drepanocytose - Google Patents
Composes et procedes de traitement de la drepanocytose Download PDFInfo
- Publication number
- WO1995011673A1 WO1995011673A1 PCT/US1994/006558 US9406558W WO9511673A1 WO 1995011673 A1 WO1995011673 A1 WO 1995011673A1 US 9406558 W US9406558 W US 9406558W WO 9511673 A1 WO9511673 A1 WO 9511673A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pantetheine
- pantethine
- hydrogen
- liq
- patient
- Prior art date
Links
- 0 CC(C)(C*)CCNCC*(*CCS*)=O Chemical compound CC(C)(C*)CCNCC*(*CCS*)=O 0.000 description 2
- SYOVTENSLJDKPI-UHFFFAOYSA-N CNC1OC1=C Chemical compound CNC1OC1=C SYOVTENSLJDKPI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
Definitions
- cyclic acetals or ketals are achieved when X and Y taken together are represented by structure 7
- cyclic orthoesters are produced when X and Y taken together are selected from structures 8, 9 or 10.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like.
- the formulations may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and the like.
- the derivatives of the present invention may also be pantetheine or pantethine cyclic carbonates.
- the carbon bridge is a single carbonyl group as illustrated in structure 13.
- Such cyclic carbonates may be prepared by treating pantetheine or pantethine with phosgene or its synthetic equivalent.
- pantothenic acid may be treated with a ketal of acetone such as 2,2-dimethoxypropane (acetone dimethyl ketal) under acidic reaction conditions, to provide the acetone ketal of pantothenic acid by a process referred to as trans-ketalization.
- the acetone ketal is exchanged or transferred from the ketalizing reagent, 2,2-dimethoxypropane, to pantothenic acid.
- a solution of sodium pantothenate in acetone may be treated with a single molar equivalent of sulfuric acid followed by treatment with 2,2-dimethoxypropane.
- Figures 5A and 5B presents the results of HPLC analysis of control samples and of serum, demonstrating conversion of S-pivaloyl pantetheine to pantetheine in serum.
- Figure 5A illustrates the elution of pantetheine after incubation of serum with S-pivaloyl pantetheine as described above.
- Figure 5B shows a corresponding sample of serum which was incubated without S-pivaloyl pantetheine, and no pantetheine was detected.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des composés et des procédés de traitement de la drépanocytose par prévention ou inhibition de l'intensité et/ou de la fréquence des crises, y compris de la douleur ou de complications associées, liées à cette maladie. L'invention concerne également des composés et des procédés d'inhibition de la falsiformation des érythrocytes chez un patient. Les procédés de cette invention consistent à administrer une dose efficace de pantéthine, de pantéthéine ou bien un dérivé de celle-ci à un patient, par exemple par voie parentérale ou orale.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71046/94A AU7104694A (en) | 1993-10-27 | 1994-06-10 | Compounds and methods for treating sickle cell anemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14423993A | 1993-10-27 | 1993-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011673A1 true WO1995011673A1 (fr) | 1995-05-04 |
Family
ID=22507701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/006558 WO1995011673A1 (fr) | 1993-10-27 | 1994-06-10 | Composes et procedes de traitement de la drepanocytose |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7104694A (fr) |
WO (1) | WO1995011673A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015106240A1 (fr) * | 2014-01-13 | 2015-07-16 | The General Hospital Corporation | Composés hétéroaryle-disulfure utilisés comme effecteurs allostériques pour augmenter l'affinité de fixation d'oxygène de l'hémoglobine |
WO2014106804A3 (fr) * | 2013-01-04 | 2017-04-13 | Cellixbio Private Limited | Compositions et procédés de traitement du syndrome métabolique et du diabète |
US10376453B1 (en) | 2016-12-29 | 2019-08-13 | Korea Institute Of Ocean Science And Technology | Composition for promoting hair growth containing novel pantetheine derivative |
JP2022511469A (ja) * | 2018-11-30 | 2022-01-31 | コメット セラピューティクス インコーポレイテッド | 環状パンテテイン誘導体及びその使用 |
-
1994
- 1994-06-10 WO PCT/US1994/006558 patent/WO1995011673A1/fr active Application Filing
- 1994-06-10 AU AU71046/94A patent/AU7104694A/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
29.09.81: "NON-ENZYMATIC ACETYLATION OF HUMAN HEMOGLOBINS", BIOCHIM.BIOPHYS.ACTA, no. 670, 1902, pages 190 - 194 * |
J. DEB. BUTLER ET AL.: "Pantethine depletes cystinotic fibroblasts of cystine", J.PEDIATR., vol. 102, no. 5, May 1983 (1983-05-01), pages 796 - 798 * |
M.SAMPIETRO ET AL.: "USO DI UN' ASSOCIAZIONE FAMACOLOGICA CONTENENTE CARNITINA, PANTETINA, CALCIO E VITAMINE NELLA BETA-TALASSEMIA ETEROZIGOTE SINTOMATICO", ARCH.MED.INTERNA, vol. 36, no. 6, 1984, pages 329 - 336 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014106804A3 (fr) * | 2013-01-04 | 2017-04-13 | Cellixbio Private Limited | Compositions et procédés de traitement du syndrome métabolique et du diabète |
WO2015106240A1 (fr) * | 2014-01-13 | 2015-07-16 | The General Hospital Corporation | Composés hétéroaryle-disulfure utilisés comme effecteurs allostériques pour augmenter l'affinité de fixation d'oxygène de l'hémoglobine |
US10758569B2 (en) | 2014-01-13 | 2020-09-01 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
US10376453B1 (en) | 2016-12-29 | 2019-08-13 | Korea Institute Of Ocean Science And Technology | Composition for promoting hair growth containing novel pantetheine derivative |
JP2022511469A (ja) * | 2018-11-30 | 2022-01-31 | コメット セラピューティクス インコーポレイテッド | 環状パンテテイン誘導体及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU7104694A (en) | 1995-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0144804B1 (fr) | 2,5-Diaryltétrahydrofurannes et analogues comme antagonistes de facteur activant de thrombocytes | |
US6323234B1 (en) | Methods to treat gastrointestinal lesions and to reduce drug-induced gastrointestinal or renal toxicity | |
EP0605622A1 (fr) | Derives a substitution oxygene de produits d'addition de nucleophile-oxyde nitrique utilises comme promedicaments donneurs d'oxyde nitrique | |
EP0532466A2 (fr) | Dérivés d'acide 5-amino-4-hydroxy-hexanoique et leur application comme agents thérapeutiques | |
EP1601644B1 (fr) | Precurseurs de diaryl-2-(5h)-furanones liberateurs d'oxyde nitrique utilises comme inhibiteurs de la cyclooxygenase-2 | |
EP0312858A1 (fr) | Dérivés hétérocycliques, leur préparation et agents radio sensitifs et agents antiviraux les contenant | |
IE841992L (en) | N-heterocyclic compounds | |
JP4035759B2 (ja) | アミノアルコールリン酸化合物、製造方法、及びその利用方法 | |
FR2532648A1 (fr) | Derives de carbostyrile, leur procede de preparation et leur application en therapeutique | |
CA2521589C (fr) | Composes pour le traitement de troubles metaboliques | |
WO1996026948A1 (fr) | Derives phosphates d'urees et de thiourees bisubstituees | |
US5491254A (en) | Prostaglandin derivatives | |
US6274747B1 (en) | Polyunsaturated fatty acid derivatives and their use | |
WO1995011673A1 (fr) | Composes et procedes de traitement de la drepanocytose | |
EP0947503B1 (fr) | Dérivés de l'acide 6,8-dimercaptooctanoique substitués en 6-S et/ou 8-S par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinées au traitement de tumeurs cancéreuses | |
US20230338311A1 (en) | Suppression of inflammasome activation | |
JP2795421B2 (ja) | N−アシルジペプチド、その製造方法及びそれを含有する製薬組成物 | |
EP1974732A1 (fr) | Agent therapeutique pour une maladie neurodegenerative | |
US5061711A (en) | Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters | |
US5089492A (en) | Pharmaceuticals and dietetics containing acylamino acid derivatives | |
EP1325904A1 (fr) | Nouveaux composes aliphatiques, procede de preparation et utilisation associes | |
US6242476B1 (en) | Leukotriene A4 hydrolase inhibitors | |
US4946963A (en) | Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones | |
US5698585A (en) | Pharmaceutical preparation for prevention and/or treatment for cataract | |
EP0618222A2 (fr) | Derivés dipeptidiques de l'acide 5-amino-4-hydroxy-hexanoique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Free format text: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |